Bicycle Therapeutics plc (BCYC)
Pre-market:
| Previous close | 23.45 |
| Open | 23.66 |
| Bid | 24.11 x 100 |
| Ask | 24.27 x 200 |
| Day's range | 23.38 - 24.71 |
| 52-week range | 12.54 - 28.91 |
| Volume | |
| Avg. volume | 396,393 |
| Market cap | 918.809M |
| Beta (5Y monthly) | 0.89 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -5.08 |
| Earnings date | 02 May 2024 - 06 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 43.20 |
- GuruFocus.com
Bicycle Therapeutics PLC (BCYC) Q1 2024 Earnings: Narrowing Losses Amidst Robust R&D Progress
Comparison with Analyst Estimates and Strategic Developments
- Business Wire
Bicycle Therapeutics Reports Recent Business Progress and First Quarter 2024 Financial Results
CAMBRIDGE, England & BOSTON, May 02, 2024--Bicycle Therapeutics plc (NASDAQ: BCYC), a biopharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today reported recent business progress and financial results for the first quarter ended March 31, 2024.
- Business Wire
Bicycle Therapeutics Announces Two Abstracts Accepted for Presentation at the 2024 ASCO Annual Meeting
CAMBRIDGE, England & BOSTON, April 24, 2024--Bicycle Therapeutics plc (NASDAQ: BCYC), a biopharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced the acceptance of two abstracts for poster presentation at the 2024 American Society for Clinical Oncology (ASCO) Annual Meeting, taking place May 31-June 4 in Chicago.
